An early interim analysis indicated highly significant prolongation of disease-free survival for all treated patients and an overall survival benefit for some subgroups (Cascinelli et al, 1994).
← all excerpts
Adjuvant therapy for melanoma: How should we respond to high-dose interferon?
1
—
—